Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 26, 2021 07:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa

Topline results anticipated in the fourth quarter of 2021Of the 31 patients enrolled in the trial, 29 patients completed the study with no missing visits, including the three primary endpoint...